Cardiovascular Study Articles & Analysis
11 news found
Ace Therapeutics is proud to announce the launch of its cardiovascular disease model development services, aiming to empower researchers and pharmaceutical companies with advanced tools and models to accelerate the study of cardiovascular diseases and drug discovery. ...
This offering accelerates researchers’ studies of diseases related to arterial tissue. Another example is the Cardiovascular Disease Tissue Microarray, 48 Cases, 24 Cores (Catalog # CSCT003), which consists of samples of cardiovascular disease tissue. It comprises 9 cases of cardiovascular tumor, 7 cases of ...
Our latest publication in Cardiovascular Engineering and Technology showcases the feasibility and functionality of our VCAST technology, a patented, AI-based medical system developed for non-invasive, clinical quantitative and qualitative analysis of CT-scan data, to assess the hemodynamic significance of coronary artery atherosclerotic stenosis. ...
CHMP opinion is based on the results from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), which included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD associated with T2D The positive data from FIGARO-DKD demonstrated that ...
ByBayer AG
Food and Drug Administration (FDA) for a label update for Kerendia™ (finerenone) to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The positive data from the pivotal Phase III FIGARO-DKD study demonstrated that finerenone ...
ByBayer AG
New Phase III study VICTOR will assess vericiguat efficacy and safety in patients who have not had a recent worsening heart failure event / VICTOR expands upon the Phase III VICTORIA study, providing further insight into the use of vericiguat in a broader range of patients with chronic heart failure with reduced ejection fraction Bayer and its development ...
ByBayer AG
The presentation, entitledEffect of Icosapent Ethyl (IPE) on Changes in Coronary Plaque Morphology, details the effects of IPE on cardiovascular events and plaque characteristics using the ElucidVivo software on CT angiography (CTA). The ElucidVivo software is the first and only FDA-cleared arterial analysis tool designed to quantify morphology from CTA as if performed ex vivo by ...
ByElucid
VANCOUVER, British Columbia — Kardium Inc. today announced that the Globe® Mapping and Ablation System has successfully demonstrated safety and efficacy in the GLOBAL-AF study. The results of the study were published in the Journal of Cardiovascular Electrophysiology. The study demonstrated a 76% percent freedom from ...
Tudorza®’s expanded label now includes data from the phase IV ASCENT study, which was conducted in patients with moderate to very severe COPD and cardiovascular disease and / or significant cardiovascular risk factors. The study demonstrated that Tudorza® is effective at reducing COPD exacerbations with no increase ...
Tudorza®’s expanded label now includes data from the phase IV ASCENT study, which was conducted in patients with moderate to very severe COPD and cardiovascular disease and / or significant cardiovascular risk factors. The study demonstrated that Tudorza® is effective at reducing COPD exacerbations with no increase ...
It found that the absence of regular physical exercise is an actual cause of many of the risk factors associated with chronic diseases, including diabetes and cardiovascular disease. The study combined the knowledge of experts from the University of Copenhagen and the Missouri-Columbia College of Veterinary Medicine. ...